###### Strengths and limitations of this study

-   The Keio interhospital Cardiovascular Studies-atrial fibrillation registry is a multicentre, registry-based prospective cohort study designed to specifically collect clinical information on newly-referred atrial fibrillation patients in Japan.

-   All patients were requested to answer the Atrial Fibrillation Effect on Quality-of-Life questionnaire both at baseline and 1 year, with planned clinical follow-up for 5 years.

-   To ensure consecutive case enrolment, a dedicated study coordinator and investigator performed on-site auditing to ensure proper registration of each eligible patient and all of the clinical endpoints were validated.

-   Potential limitation includes observational design and generalisability of the study results (the study was conducted in University affiliated hospitals within Tokyo metropolitan area).

Introduction {#s1}
============

Atrial fibrillation (AF) is the most frequently encountered sustained arrhythmia and is associated with substantial morbidity and mortality and impaired quality-of-life (QOL) worldwide.[@R1] Further, AF is known to constitute a significant public health problem, and estimates suggest that this condition accounts for 1% of the National Health Service budget in UK[@R5] and \$16--26 billion of annual US healthcare expenditures.[@R6] The incidence of AF is known to increase rapidly with advancing age and its burden is expected to continue to rise.[@R7] An estimated 700 000 people in Japan have AF, which is projected to increase to \>1 million by 2050.[@R8]

Over the last decade, efficacy of new therapies for both stroke prevention (ie, non-vitamin K antagonist oral anticoagulants (NOACs)) and rhythm control has been demonstrated.[@R10] Although these and other studies have advanced our knowledge of AF, many of the prior clinical studies and registries have focused on all-comer AF patients; hence their patient background varied significantly, and the implications for actual patient care remain limited.[@R11] Moreover, data on the patient perception, including patient-reported outcomes (PROs) remain scarce; this is mainly due to relatively small sample sizes, restricted follow-up and the lack of validated AF-specific QOL assessments. Therefore, it is of utmost importance to clarify the profiles of patients, including the QOL assessment to identify country-specific gaps and areas for improvement, particularly in Japan, where social health insurance was implemented in 1961.[@R12]

The Keio interhospital Cardiovascular Studies-atrial fibrillation (KiCS-AF) registry is a multicentre, prospective cohort study of patients with newly-diagnosed or referred AF. The registry collects information regarding patient-reported QOL and also assesses its association with individual treatment strategies, including rate and rhythm control, and stroke prophylaxis, within contemporary Japanese clinical practice. The present report describes the clinical characteristics of patients with newly-diagnosed or referred AF in Japan based on the preliminary data collected in this study, and the similarities and differences in characteristics of these patients compared with those in Western countries.

Cohort description {#s2}
==================

Registry objectives {#s2-1}
-------------------

The objectives of the KiCS-AF registry are as follows: (1) describe non-selected AF patients in Japanese routine clinical practice, including patients' demographics, comorbidities and risk profiles using a contemporary scoring system; (2) explore the adoption and impact of emerging anticoagulant, rate-control and antiarrhythmic therapies (eg, catheter ablation for AF or use of antiarrhythmic drugs) on PROs and use of healthcare resources and (3) evaluate long-term clinical outcomes in patients with AF within contemporary Japanese practice.

Participants {#s2-2}
------------

Patients meeting inclusion criteria were registered by investigators ([table 1](#T1){ref-type="table"}). All patients more than 20 years old with electrocardiographically documented AF (eg, by ECG, Holter monitoring, implanted device and so on) were eligible, including patients with both valvular and non-valvular AF. Patients with atrial flutter alone were not eligible. The registry included patients with prevalent or incident AF who were newly referred to the network hospitals within the previous 6 months. A dedicated clinical research coordinator screened the patients from an administrative dataset provided monthly by each hospital, and query for study participation was sent to the physicians who set the appointments with patients under the new diagnostic coding of AF. When deemed eligible by the treating physicians, patients were requested to participate in the registry within 1--6 months from their initial visit. All participants provided written informed consent. Patients were enrolled both from inpatient and outpatient settings and patients with AF due to a reversible cause (eg, thyroid disease or postoperative AF) were included in this registry.

###### 

Inclusion and exclusion criteria

  Inclusion criteria                                                                                                                                                                                                                                          Exclusion criteria
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Age ≥20 years.Electrocardiographically confirmed AF.Patients with prevalent or incident AF who were newly referred to the network hospitals within the previous 6 months.Anticipated, regular annual follow-up outpatient visits.Signed informed consent.   Atrial flutter only without AF.Current participation in a randomised clinical study for AF.Patients who are not considered suitable by the attending physicians.

AF, atrial fibrillation.

The KiCS-AF registry started enrolling patients in September 2012 and enrolment was completed by June 2018. A total of 11 institutions within the Tokyo metropolitan area in Japan (Saitama, Tochigi, Chiba, Kanagawa and Tokyo Prefecture) participated in the study; most are large tertiary care referral centres ([figure 1](#F1){ref-type="fig"}; over 70% with \>500 beds). The enrolment starting dates vary between participating hospitals since approval dates by the individual ethics committee differed. A total of 11 hospitals completed its enrolment in June 2018.

![Geographic distribution of Keio interhospital Cardiovascular Studies-atrial fibrillation enrolling sites. A total of 11 hospitals completed its enrolment in June 2018.](bmjopen-2019-032746f01){#F1}

Data collection and follow-up {#s2-3}
-----------------------------

The primary data source was the medical records of registered patients. Dedicated clinical research coordinators were assigned and trained for the present registry; the coordinators have met biannually for updates and to discuss the queries from each institution. In collaboration with the primary site investigators (listed in the Collaborators section), coordinators were instructed to record and register data from consecutive hospital visits for patients with AF using an internet-based data collection system. Data quality assurance was achieved through automatic system validation and reporting of data completeness. PROs' questionnaires were aimed to be administered to all patients at the baseline visit and during follow-up visits or by mail. Yearly follow-up examinations were performed for all patients by mail, phone interviews and chart reviews. Trained study coordinators also transcribed the PROs' questionnaires and updated the status of major cardiovascular events and procedures and subsequent medication changes, and laboratory test values were collected.

Data collection was ensured at 1-year intervals for a minimum of 2 years after registration ([table 2](#T2){ref-type="table"}). Data collection windows were expanded to 6 months in either direction to maximise data collection during patients' follow-up visits. Baseline data include patient backgrounds, symptoms, prior and current drug use (including oral anticoagulants (OACs) and antiplatelet agents), ECGs, echocardiograms and blood sampling test results. Patient background factors included parameters for calculating risk scores for stroke, for example, congestive heart failure, hypertension, age ≥75 years, diabetes mellitus and stroke for the CHADS~2~ score[@R13]; cardiac failure or dysfunction, hypertension, age ≥75 years, diabetes, stroke including vascular disease, age 65--74 years and sex category (female) for the CHA~2~DS~2~-VASc score.[@R14] OACs included warfarin and direct OACs (ie, dabigatran, rivaroxaban, apixaban and edoxaban), and antiplatelet agents included aspirin, clopidogrel and prasugrel. Blood samples were analysed for complete blood count, liver function, kidney function, coagulation and serum brain natriuretic peptide level. In detail, data regarding anticoagulant therapies, dosage and discontinuations were collected as follow-up medication data. For patients prescribed warfarin, international normalised ratio values were collected. The definitions of each variable are available in the [online supplementary material](#SP1){ref-type="supplementary-material"}.
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###### 

Timeline of data collection in KiCS-AF

                                                                               Baseline   1 year   2 years
  ---------------------------------------------------------------------------- ---------- -------- ---------
  Demographics, medical history and AF diagnosis                               **X**               
  Vital signs, laboratory data, ECG and echo data                              **X**      **\***   **\***
  Current pharmacotherapies (including PT-INR monitoring) and adverse events   **X**      **X**    **X**
  Temporary and permanent discontinuation of antithrombotic therapies                     **X**    **X**
  Details of cardiac procedures                                                           **X**    **X**
  Outcomes                                                                                **X**    **X**
  Patient-reported outcomes (ie, AFEQT)                                        **X**      **X**    

The data on ECG only were obtained at each follow-up.

AF, atrial fibrillation; AFEQT, Atrial Fibrillation Effect on Quality-of-Life; KiCS-AF, the Keio interhospital Cardiovascular Studies-atrial fibrillation; PT-INR, prothrombin time-international normalised ratio.

Patient-reported outcomes {#s2-4}
-------------------------

All patients completed a detailed questionnaire regarding QOL and their perception of treatment at baseline and at 1-year follow-up by using the internationally validated Atrial Fibrillation Effect on Quality-of-Life (AFEQT; <http://www.afeqt.org>) questionnaire. The development and validation of AFEQT have been previously described.[@R15] It is a 20-item questionnaire that quantifies four domains of AF-related QOL including symptoms, daily activities, treatment concern and treatment satisfaction by using 7-point Likert response scales. An overall summary score can be calculated from the first three domains, which range from 0 to 100 (100, best possible health status (no impairment); 0, worst health status). A culturally and linguistically translated version of AFEQT for Japan was used. Furthermore, patients' subjective complaints, including palpitation, dyspnoea on exertion, difficulty of activities, dizziness, fatigue, chest pain and syncope, were evaluated by a physician at an initial medical interview in an outpatient clinic before access to patients' AFEQT questionnaires and immediately after enrolment.

Outcomes {#s2-5}
--------

The primary outcome event in KiCS-AF was stroke or systemic embolism. Stroke was defined as a new, sudden, loss of neurological function with residual symptoms lasting at least 24 hours after onset and is not due to a non-vascular cause (eg, seizure). Primary outcome events were confirmed by document submission and central review at the data coordinating centre. The primary safety outcome of interest was major bleeding, as defined by the International Society of Thrombosis and Hemostasis criteria,[@R16] which included bleeding events meeting at least one of the following criteria:

1.  Fatal bleeding, and/or

2.  Symptomatic bleeding in a critical area or organ (such as intracranial, intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, or intramuscular with compartment syndrome), and/or

3.  Bleeding causing a fall in haemoglobin level by 20 g/L or more or leading to transfusion of two or more units of whole blood or red cells.

Secondary outcomes included all causes of death and hospitalisation. Death is classified into 1 of 3 categories: (1) cardiovascular death; (2) non-cardiovascular death and (3) undetermined cause of death. Cardiovascular death was subcategorised based on the cardiovascular aetiology of the death, which included acute myocardial infarction, sudden cardiac death, heart failure, stroke and other cardiovascular causes (eg, pulmonary embolism, aortic dissection, aortic aneurysm or peripheral arterial disease). Specific definitions of each outcome were described in [online supplementary table 1](#SP1){ref-type="supplementary-material"}. All causes of hospitalisation were categorised as cardiovascular (eg, acute coronary syndrome, coronary revascularisation and acute heart failure) or non-cardiovascular hospitalisations. Use of AF-related procedures---including catheter ablation, pacemaker implantation, cardioversion, atrioventricular node ablation and left atrial appendage closure---were recorded for analysis.

Sample size {#s2-6}
-----------

The goal of enrolling 3333 patients is to capture a large representative population of Japanese patients with AF. Based on recently completed clinical trials and observational studies, we anticipate an incident stroke rate of 2.4%--3.0% in our unselected KiCS-AF population.[@R17] This would correspond to approximately 80 strokes by the end of the follow-up period. In addition, to compare patients' reported QOL scores in four analytic groups (two study groups (warfarin and non-warfarin) and two strata (incident and prevalent)), we will require 1500 patients in each group to have 80% power to detect a 2-point difference in the mean score of an item between two groups (assuming an SD of unity, a two-sided α=0.05)

Statistical analyses {#s2-7}
--------------------

Statistical plans varied according to specific analyses. Yet, there were certain considerations incorporated in all analyses of KiCS-AF. Importantly, several adjustment methodologies, including multivariable adjustment, or other methods have been considered when comparing patients. Continuous variables were summarised by medians with 25th and 75th percentiles, or by means with SD, and categorical variables were presented as numbers and percentages. Associations were reported using hazards ratios (eg, for COX regression models) or odds ratios (eg, for logistic regression models) with 95% confidence intervals. All reported p values were two-sided with a p value \<0.05 being considered statistically significant.

Patients involvement {#s2-8}
--------------------

Patients and the public were not involved in the development of the research question, the design of the study, the recruitment and the conduct of the research.

Information disclosure {#s2-9}
----------------------

The KiCS-AF Steering Committee was responsible for overall study guidance, including the study protocol, data analysis and interpretation of results. Before the launch of the KiCS-AF registry, information regarding the objectives of the study and its social significance were provided for clinical trial registration with the University Hospital Medical Information Network (UMIN 000022229). This network is recognised by the International Committee of Medical Journal Editors as an 'acceptable registry' according to a statement issued in September 2004.

Findings to date {#s3}
================

As of December 2016, a total of 2464 patients were enrolled from 11 institutions. Almost all patients agreed to participate. The number of patients who refused to participate was only available from a limited number of participating centres. The refusal rate was 3.1% (42/1322, [online supplementary table 2](#SP1){ref-type="supplementary-material"}). At that time, 2307 patients (93.6%) had completed the 1-year follow-up, and 2072 patients (89.8%) had 1-year follow-up AFEQT data.

Patients demographics within the KiCS-AF registry {#s3-1}
-------------------------------------------------

The characteristics of these patients are shown in [table 3](#T3){ref-type="table"}. The mean age was 67.1 years (SD, 11.7) and 69.7% (n=1717) were men. Almost half (49.2%) of the patients presented with paroxysmal AF, while only 6% had first-detected AF. In addition, a quarter of patients had AF diagnosed during routine medical screening programme. The mean and median CHA~2~DS~2~-VASc scores in the KiCS-AF registry was 2.3 (SD, 1.6) and 2 (IQR, 1--3), respectively. OAC therapy was used for 88.6% of patients with stroke risk (ie, CHA~2~DS~2~-VASc score ≥2), 1637 patients (66.4%) were prescribed NOACs, and 384 patients (15.6%) were prescribed warfarin. Of note, almost half of the registered patients (53.5%) opted for a rhythm control strategy.

###### 

Baseline characteristics

  -----------------------------------------------------------------
  Characteristics                        KiCS-AF, n=2464, no. (%)
  -------------------------------------- --------------------------
  Age, median (IQR), years               68 (60--75)

  Men                                    1717 (69.7)

  BMI, median, kg/m^2^ (IQR)             23.2 (21.1--25.5)

  Heart rate, median, bpm (IQR)          78 (67--90)

  Blood pressure, median, mm Hg (IQR)    

   Systolic                              128 (117--139)

   Diastolic                             76 (69--85)

  Medical history                        

   Smoking                               407 (16.5)

   Hypertension                          1369 (55.6)

   Diabetes mellitus                     402 (16.3)

   Dyslipidaemia                         810 (32.9)

   Heart failure                         385 (15.6)

   Obstructive sleep apnoea              73 (3.0)

   Stroke or TIA                         211 (8.6)

   Gastrointestinal bleeding             34 (1.3)

   CKD (eGFR \<60 mL/min)                1011 (41.0)

   CKD on HD                             16 (0.6)

   Peripheral artery disease             82 (3.3)

   Coronary artery disease               196 (8.0)

  Prior revascularisation                

   Prior PCI                             122 (5.0)

   Prior CABG                            21 (0.9)

   Prior valve surgery                   39 (1.6)

  BNP, median, pg/mL (IQR)               91.8 (38.4--183.6)

  CHADS~2~ score, mean (SD)              1.3 (1.2)

  CHADS~2~ score, median (IQR)           1 (0--2)

  CHA~2~DS~2~-VASc score, mean (SD)      2.3 (1.6)

  CHA~2~DS~2~-VASc score, median (IQR)   2 (1--3)

  LVEF, median, % (IQR)                  60 (58.7--60)

  LA diameter, median, cm (IQR)          4.1 (3.6--4.6)

  Type of visit                          

   Diagnosed at health screening         642 (26.1)

   Referral from emergency department    224 (9.1)

  Type of AF                             

   First detected/new onset              147 (6.0)

   Paroxysmal                            1213 (49.2)

   Persistent                            665 (27.0)

   Permanent                             375 (15.2)

  Current drug therapy                   

   β-blockers                            1314 (53.3)

   ACE inhibitors/ARBs                   863 (35.0)

   Calcium-channel blockers              972 (39.4)

   Digoxin                               157 (6.4)

   Diuretics                             513 (20.8)

  Currently using antiarrhythmic drugs   

   Overall                               526 (21.3)

   Cibenzoline                           66 (2.7)

   Disopyramide                          29 (1.2)

   Pilsicainide                          190 (7.7)

   Flecainide                            63 (2.6)

   Amiodarone                            29 (1.2)

   Bepridil                              135 (5.5)

  Oral anticoagulants                    

   Overall                               2021 (82.0)

   Warfarin                              384 (15.6)

  Direct oral anticoagulants             

   Overall                               1637 (66.4)

   Dabigatran                            265 (10.8)

   Rivaroxaban                           628 (25.5)

   Apixaban                              630 (25.6)

   Edoxaban                              114 (4.6)

   Concomitant antiplatelet therapy      316 (12.8)

   Oral anticoagulation in those with\   1439 (88.6)
   CHA~2~DS~2~-VASc score \>2            

  Prior interventional therapy for AF    

   Catheter ablation of AF               160 (6.5)

   AV node/His bundle ablation           16 (0.6)

   Surgical maze                         7 (0.3)

  Rhythm control strategy                1319 (53.5)

  Rate control strategy                  1126 (45.7)
  -----------------------------------------------------------------

ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker;AV node, atrioventricular node; BMI, body mass index; BNP, brain natriuretic peptide;bpm, beats per minute; CABG, coronary artery bypass grafting; CKD, chronic kidney disease;eGFR, estimated glemerular filtration rate; HD, haemodialysis;KiCS-AF, the Keio interhospital Cardiovascular Studies-atrial fibrillation; LA, left atrium; LVEF, left ventricular ejection fraction;PCI, percutaneous coronary intervention; TIA, transient ischaemic attack.

The present report indicates that patients enrolled in the KiCS-AF were younger, more likely to be male, less likely to have cardiac comorbidities, and consequently had lower CHA~2~DS~2~-VASc scores, compared with previous reports from Western registries, such as Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) ([table 4](#T4){ref-type="table"}).[@R19] Frequent diagnosis during the annual health screening programme (ie, typical Japanese workers are eligible to undergo annual health screenings that include a 12-lead ECG examination) may contribute to these differences. No data specifically addressed the risk of stroke and death in screen-detected AF in the general population. Future studies that ascertain the actual impact of screen-detected AF on both clinical and PROs will inform AF practice and further optimise care.

###### 

Characteristics of AF registries that obtained quality-of-life measures

  Registry                                     KiCS-AF                               ORBIT-AF[@R29]   RECORD- AF[@R28]                     Euro Heart Survey on AF[@R30]
  -------------------------------------------- ------------------------------------- ---------------- ------------------------------------ -------------------------------
  Study period                                 2012--2018                            2009--2011       2007--2008                           2003--2004
  Population                                   Inpatient and outpatient              Outpatient       Inpatient and outpatient             Inpatient and outpatient
  Enrolment                                    3333                                  10 000           5333                                 5604
  Patients that completed QOL questionnaires   3333                                  2007             2439                                 967
  Quality-of-life measures                     AFEQT (cross-validated translation)   AFEQT and ACTS   Atrial Fibrillation Severity Scale   EuroQoL-5 domains
  Countries                                    Japan                                 USA              21 throughout the world              35 in Europe
  No. of sites                                 11                                    200              532                                  182
  Patients' characteristics, %                                                                                                             
   Age (mean, years)                           68                                    76               67.6                                 63.3
   Female                                      30.2                                  43.2             41.5                                 43.1
   Heart failure                               15.6                                  27.3             16.4                                 17.7
   Hypertension                                55.6                                  82.6             NA                                   61.3
   Diabetes                                    16.3                                  27.6             NA                                   13.1
   Prior stroke/TIA                            8.6                                   8.9              NA                                   2.4
   Prior coronary artery disease               8                                     31.4             NA                                   25
   Paroxysmal AF                               49.2                                  47.6             51.5                                 84.7
   Mean CHA~2~DS~2~-VAsc score                 2.3                                   NA               NA                                   2.5

ACTS, anticoagulation-related quality-of-life assessment transient ischaemic attack; AF, atrial fibrillation; AFEQT, Atrial Fibrillation Effect on Quality-of-Life;KiCS-AF, the Keio interhospital Cardiovascular Studies-atrial fibrillation; ORBIT-AF, Outcomes Registry for Better Informed Treatment of Atrial Fibrillation;QOL, quality-of-life; RECORD-AF, Registry on Cardiac Rhythm Disorders Assessing the Control of Atrial Fibrillation; TIA, transient ischaemic attack.

In addition, regarding the management strategy of AF, NOACs were more commonly used in Japan compared with previous reports from Western countries.[@R20] This finding may be attributable to the following: (1) prescriptions are covered by the National Health Insurance system in Japan[@R12]; (2) physicians may readily prescribe medications, as there are no pre-specified restrictions and (3) a growing body of data suggests that NOACs may be preferred for East Asian populations.[@R21] It has been widely recognised that Asian patients treated with OAC therapy are known to have a higher risk of bleeding complications, and a much lower proportion of time-in-therapeutic range (44%--68%) with warfarin compared with Western data was reported.[@R22]

Symptoms and QOL {#s3-2}
----------------

The distribution of AF related symptoms is reported in [figure 2](#F2){ref-type="fig"}. The most common symptoms that patients complained of at registration were palpitations (41.3%) followed by dyspnoea (16.4%), while 41.8% of patients were asymptomatic at the time of registration. The median AFEQT-overall summary score was 79.1 (IQR, 66.6--89.1). A breakdown of each of the four domains is described in [figure 3](#F3){ref-type="fig"}. Importantly, these results suggest that roughly 50% of the patients in the KiCS-AF had an impaired QOL at baseline.[@R24] In addition, regardless of differences in patients' backgrounds, our findings regarding baseline AFEQT-overall summary score are in line with that of previous reports from the ORBIT-AF registry.[@R4] Further investigations aimed at providing care and its association with patient-reported QOL may aid the development of a roadmap for global AF-related quality improvement and educational initiatives.

![Distribution of symptoms for atrial fibrillation at the time of registration. Each bar shows atrial fibrillation symptom frequencies.](bmjopen-2019-032746f02){#F2}

![AFEQT survey results at the time of registration. The dark line in the middle of the boxes is the median of each score. The bottom of the box indicates the 25th percentile, and the top of the box represents the 75th percentile. Approximately 95% of the data are expected to lie between the inner fences. AFEQT, Atrial Fibrillation Effect on Quality-of-Life.](bmjopen-2019-032746f03){#F3}

Strengths and limitations {#s4}
=========================

The KiCS-AF provides detailed data on the demographics, risk profiles, patterns of care and subsequent outcomes (including PROs) of contemporary Japanese patients with AF and, thus far, has revealed several important differences compared with patients with AF in Western countries. It is important to determine the clinical characteristics and profiles of patients with AF in different regions. Such data are necessary for benchmarking, and enables comparisons across different countries, populations and healthcare systems.

Prior registries in Japan have examined the management of patients with AF mainly focused on their clinical outcomes.[@R25] Although these and other registries have advanced our knowledge of AF, they have been limited by relatively old studies from a non-NOAC predominant era (ie, dabigatran was approved by Pharmaceuticals and Medical Devices Agency in Japan in 2011) and lack of assessments on PROs ([table 5](#T5){ref-type="table"}). The KiCS-AF enrolled 3333 patients with a planned follow-up period of minimum 2 years (up to 5 years) to examine contemporary management of patients with AF in relation to patient-reported QOL outcomes. This long-term follow-up had several benefits, including a greater detection of infrequent clinical outcomes (eg, death and stroke) and the opportunity to observe trends in treatment strategies and their impacts on patient-reported QOL and other important outcomes. Furthermore, to the best of our knowledge, the KiCS-AF registry is the first study of AF to focus on PROs in the Asia Pacific region. AF is associated with significantly impaired QOL.[@R3] Accordingly, many treatment decisions in AF are intended towards preserving and/or improving patients' reported QOL. Although, prior studies of QOL have been informative but limited by several aspects, such as restricted follow-up,[@R28] relatively small sample size[@R29] and the lack of disease-specific qualify-of-life questionnaires ([table 4](#T4){ref-type="table"}).[@R30]

###### 

Characteristics of AF registries in Japan

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Registry                 Study period                Inclusion criteria                                                               Enrolment   Follow-up           No. of sites                                                  Quality-of-life measures
  ------------------------ --------------------------- -------------------------------------------------------------------------------- ----------- ------------------- ------------------------------------------------------------- --------------------------
  KiCS-AF                  September 2012--July 2018   ECG confirmed AF\                                                                3333        Minimum 2 years,\   11\                                                           AFEQT
                                                       (newly-referred patients, consecutively screened from administrative database)               up to 5 years       (Tokyo metropolitan area)                                     

  Fushimi AF[@R25]         February 2011--May 2017     ECG confirmed AF                                                                 5136        Annual follow-up\   80\                                                           NA
                                                                                                                                                    (up to 2022)        (Fushimi, Kyoto-city)                                         

  J-RHYTHM[@R26]           January 2009--July 2009     Outpatients                                                                      7937        2 years             158\                                                          NA
                                                                                                                                                                        (voluntary registered across various institutions in Japan)   

  Shinken Database[@R27]   June 2004 to current        Initial AFs                                                                      3620        Annual follow-up    1 (cardiovascular institution in Tokyo)                       NA
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

AF, atrial fibrillation; AFEQT, Atrial Fibrillation Effect on Quality-of-Life;KiCS-AF, Keio interhospital Cardiovascular Studies-atrial fibrillation; NA, not applicable.

For a thorough understanding of our results, several limitations should be acknowledged. First, non-randomised observational research involves inherent limitations, although it is the best way to describe the current treatment patterns and outcomes of care. There is likely to be unmeasured confounding, such as depression, frailty or economic status that may impact on the PROs. Second, not all AF patients in Japan participated in the KiCS-AF registry, and the sampling bias and generalisability of the study results to Japan is a potential concern, although we were very inclusive of those presenting to the participating centres with new-onset AF. As patients were primarily referred to large tertiary care referral centres in the Tokyo metropolitan area, selection bias may result in patients with AF at the outpatient clinical level in more rural areas or patient who do not require intensive cardiovascular care not being captured. Despite this potential limitation, we believe that this is one of the most representative Japanese databases of AF patients, and our results comprise the most complete assessment of current practice patterns and QOL outcomes in Japan. Third, echocardiograms were not performed as part of the study protocol for clinical reasons, and thus standardised echocardiograph protocols have not been used across all participating hospitals.

In conclusion, the KiCS-AF allowed for extensive investigation of AF-related QOL in a non-selected population over a long-term follow-up by using a rigorously validated QOL assessment tool. Our future analyses will be aimed at determining if QOL differs according to patients' backgrounds, cardiac biomarkers, echocardiography data or treatment strategies. Additional analyses will assess whether these differences in AF-related QOL are associated with differences in care providers' decisions towards implementation of rhythm control or anticoagulation strategies in routine clinical practice. In addition, QOL assessments with respect to anticoagulation therapy may aid in improvement of patient satisfaction, adherence and better physician--patient relationship. Finally, these data could also serve as a reference for indirect comparisons of QOL in experimental studies or comparative effectiveness research.[@R29]

Collaboration {#s5}
=============

The data and materials used to conduct this research are available to researchers, on request, for scientific projects aimed at identifying a novel clinical finding that may further improve patient outcome. Attempts to co-validate country‐specific observations, risk stratification schemes, and outcomes are also welcome. The procedure does need to follow the Act on the Protection of Personal Information Law (as of May 2017) and the Ethical Guidelines for Medical and Health Research Involving Human Subjects (as of March 2015) in Japan.

Supplementary Material
======================
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